2696.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 May 2024 @ 04:08):

Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases...

Stats
Today's Volume	518 000
Average Volume	252 472
Market Cap	9.36B
EPS	HKD0 ( 2024-03-20 )
Next earnings date	( HKD0 ) 2024-05-20
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	15.94
ATR14	HKD0.00800 (0.05%)

Volume Correlation

Long: -0.19 (neutral)

Short: -0.85 (strong negative)

Signal:(42.318) Neutral

Shanghai Henlius Biotech Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Shanghai Henlius Biotech Correlation - Currency/Commodity

0.74
( moderate )

0.62
( weak )

0.00
( neutral )

0.70
( moderate )

-0.65
( weak negative )

Shanghai Henlius Biotech Financials

Annual	2023
Revenue:	HKD5.39B
Gross Profit:	HKD3.92B (72.64 %)
EPS:	HKD1.010

FY	2023
Revenue:	HKD5.39B
Gross Profit:	HKD3.92B (72.64 %)
EPS:	HKD1.010

FY	2022
Revenue:	HKD3.21B
Gross Profit:	HKD2.37B (73.73 %)
EPS:	HKD-1.280

FY	2021
Revenue:	HKD1.68B
Gross Profit:	HKD1.16B (68.93 %)
EPS:	HKD-1.858

Financial Reports:

No articles found.

Shanghai Henlius Biotech

Shanghai Henlius Biotech, Inc., a biopharmaceutical company, engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and non-squamous non-small cell lung cancer (nsNSCLC); and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous non-small cell lung cancer (sqNSCLC), extensive small-cell lung cancer, metastatic esophageal squamous-cell carcinomas, neo-/adjuvant treatment of gastric cancer, hepatocellular carcinoma, mCRC, nsNSCLC, squamous cell carcinoma of the head and neck (SCCHN), and solid tumors; HLX04-O, a bevacizumab injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX07, HLX23, HLX35, HLX208, HLX55, HLX301, and HLX20 for the treatment of solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; HLX12 for gastric cancer, metastatic non-small cell lung cancer, and mCRC; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; HLX15 for multiple myeloma; and HLX71 to treat COVID-19. Shanghai Henlius Biotech, Inc. operates in Mainland China, Europe, rest of Asia Pacific, and internationally. The company was founded in 2010 and is headquartered in Shanghai, China. Shanghai Henlius Biotech, Inc. is a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.